Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Meiss

Showing results (101-110 of 110) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 110 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2019
Targeted Therapy in Advanced Melanoma With Rare <i>BRAF</i> MutationsChristian Menzer, Alexander M Menzies, Matteo S Carlino, et al.
European Journal of Cancer (Oxford, England : 1990)|August 24, 2025
Targeted therapy for rare BRAF-mutated melanoma: Updated multicenter analysis and launch of a publicly accessible online outcome databaseChristian Menzer, Susanne Dugas-Breit, Martin Dugas, et al.
Journal for Immunotherapy of Cancer|September 20, 2023
Treatment management for <i>BRAF</i>-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREGMaximilian Haist, Henner Stege, Friederike Rogall, et al.
Nature Immunology|February 2, 2023
Phosphoinositide acyl chain saturation drives CD8<sup>+</sup> effector T cell signaling and functionJoy Edwards-Hicks, Petya Apostolova, Joerg M Buescher, et al.
Cancers|April 3, 2021
Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center AnalysisRouven Hoefflin, Adriana Lazarou, Maria Elena Hess, et al.
Journal for Immunotherapy of Cancer|April 7, 2023
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREGCindy Franklin, Peter Mohr, Leonie Bluhm, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2025
First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREGSören Reinhard, Jochen Sven Utikal, Anne Zaremba, et al.
Cancer Cell|February 11, 2025
Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunityLukas M Braun, Sophie Giesler, Geoffroy Andrieux, et al.
European Journal of Cancer (Oxford, England : 1990)|December 6, 2024
Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy - A multicenter study on 2419 patients from the prospective skin cancer registry ADORegJulian Kött, Tim Zell, Noah Zimmermann, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 26, 2022
Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and SwitzerlandKatharina Schumann, Cornelia Mauch, Kai-Christian Klespe, et al.
Pageof 11

Showing results (101-110 of 110) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 110 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2019
Targeted Therapy in Advanced Melanoma With Rare <i>BRAF</i> MutationsChristian Menzer, Alexander M Menzies, Matteo S Carlino, et al.
European Journal of Cancer (Oxford, England : 1990)|August 24, 2025
Targeted therapy for rare BRAF-mutated melanoma: Updated multicenter analysis and launch of a publicly accessible online outcome databaseChristian Menzer, Susanne Dugas-Breit, Martin Dugas, et al.
Journal for Immunotherapy of Cancer|September 20, 2023
Treatment management for <i>BRAF</i>-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREGMaximilian Haist, Henner Stege, Friederike Rogall, et al.
Nature Immunology|February 2, 2023
Phosphoinositide acyl chain saturation drives CD8<sup>+</sup> effector T cell signaling and functionJoy Edwards-Hicks, Petya Apostolova, Joerg M Buescher, et al.
Cancers|April 3, 2021
Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center AnalysisRouven Hoefflin, Adriana Lazarou, Maria Elena Hess, et al.
Journal for Immunotherapy of Cancer|April 7, 2023
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREGCindy Franklin, Peter Mohr, Leonie Bluhm, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2025
First-line checkpoint inhibitor therapy in metastatic acral lentiginous melanoma compared to other types of cutaneous melanoma: A multicenter study from the prospective skin cancer registry ADOREGSören Reinhard, Jochen Sven Utikal, Anne Zaremba, et al.
Cancer Cell|February 11, 2025
Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunityLukas M Braun, Sophie Giesler, Geoffroy Andrieux, et al.
European Journal of Cancer (Oxford, England : 1990)|December 6, 2024
Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy - A multicenter study on 2419 patients from the prospective skin cancer registry ADORegJulian Kött, Tim Zell, Noah Zimmermann, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 26, 2022
Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and SwitzerlandKatharina Schumann, Cornelia Mauch, Kai-Christian Klespe, et al.
Pageof 11